The role of EZH2 in paediatric myelodysplasia

The role of EZH2 in paediatric myelodysplasia

<p><em>Background:</em> Fetal haematopoiesis has clear functional and molecular differences to adult haematopoiesis. Some leukaemias, such as juvenile myelomonocytic leukaemia (JMML), are believed to originate in fetal cells, and frequently have a poor prognosis. The majority of pa...

Descripció completa

Dades bibliogràfiques
Autor principal:	Fordham, N
Altres autors:	Mead, A
Format:	Thesis
Idioma:	English
Publicat:	2021

Ítems similars

Chromosomal deletions in myelodysplasia.
per: Boultwood, J, et al.
Publicat: (1995)

Temozolomide-Induced Myelodysplasia
per: Ethan A. Natelson, et al.
Publicat: (2010-01-01)

Solving the mystery of myelodysplasia.
per: Jerald Radich
Publicat: (2008-02-01)

Introduction to the Review Series on Myelodysplasia
per: Moshe Mittelman
Publicat: (2025-01-01)

Acquired spherocytosis in the setting of myelodysplasia
per: Linda Katharina Karlsson, et al.
Publicat: (2022-01-01)

Hemophagocytic Lymphohistiocytosis Complicating Myelodysplasia
per: Geraldine Quintero-Platt, et al.
Publicat: (2014-03-01)

Peculiarities of myelodysplasia syndrome course of children
per: I. I. Balasheva, et al.
Publicat: (2003-09-01)

Glutathione S-transferase gene deletions in myelodysplasia.
per: Atoyebi, W, et al.
Publicat: (1997)

Ha-ras hypervariable alleles in myelodysplasia.
per: Thein, S, et al.
Publicat: (1986)

Myelodysplasia Rehabilitation in Children: a Review
per: Anna M. Nekrasova, et al.
Publicat: (2024-10-01)

New Insights on Iron Study in Myelodysplasia
per: Noha M. El Husseiny, et al.
Publicat: (2014-12-01)

Myelodysplasia and Mast Cell Leukemia with t(9;22)
per: Kathryn J. Lago, et al.
Publicat: (2017-01-01)

The role of EZH2-VAV interaction in tumorigenesis
per: Wong, Jong Fu
Publicat: (2015)

The Potential Roles of EZH2 in Regenerative Medicine
per: Ruey-Hwang Chou, et al.
Publicat: (2015-03-01)

THE VALUE OF URINARY BDNF, ATP AND MMP-2 IN CHILDREN WITH MYELODYSPLASIA
per: C Sekerci, et al.
Publicat: (2023-09-01)

Distinct and separable roles for EZH2 in neurogenic astroglia
per: William W Hwang, et al.
Publicat: (2014-05-01)

Gene expression and risk of leukemic transformation in myelodysplasia
per: Shiozawa, Y, et al.
Publicat: (2017)

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog
per: Ethan A. Natelson, et al.
Publicat: (2013-01-01)

Therapy-related leukemia and myelodysplasia: susceptibility and incidence
per: Giuseppe Leone, et al.
Publicat: (2007-10-01)

Leishmaniasis presenting as myelodysplasia: A diagnostic dilemma
per: Amita Jain Gupta, et al.
Publicat: (2018-01-01)

Pathophysiology and treatment of myelodysplasia with del(5q)
per: Bello, E
Publicat: (2017)

The epigenetic role of EZH2 in acute myeloid leukemia
per: Jinyong Fang, et al.
Publicat: (2024-12-01)

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
per: Haruka Shinohara, et al.
Publicat: (2022-12-01)

TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA
per: Ugo Testa, et al.
Publicat: (2023-06-01)

Real‐world study of the use of azacitidine in myelodysplasia in Australia
per: Anoop Enjeti, et al.
Publicat: (2024-06-01)

Myelodysplasia in younger adults: outlier or unique molecular entity?
per: David A. Sallman, et al.
Publicat: (2017-06-01)

Hyperfibrotic myelodysplasia: case report with response to steroid therapy
per: Maura Romeo, et al.
Publicat: (2002-01-01)

EZH2 in Myeloid Malignancies
per: Jenny Rinke, et al.
Publicat: (2020-07-01)

The Roles of the Histone Protein Modifier EZH2 in the Uterus and Placenta
per: Ana M. Mesa, et al.
Publicat: (2020-09-01)

EZH2: Its regulation and roles in immune disturbance of SLE
per: Yiying Yang, et al.
Publicat: (2022-10-01)

Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.
per: Pedersen-Bjergaard, J, et al.
Publicat: (2002)

Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia
per: Aristides Armas, et al.
Publicat: (2017-01-01)

Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients
per: Robert Morlock, et al.
Publicat: (2024-06-01)

Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
per: Gregory A. Abel, et al.
Publicat: (2016-06-01)

MYELODYSPLASIA/MYELOPROLIFERATIVE WITH RING SIDEROBLAST AND THROMBOCYTOSIS OR UNCLASSIFIABLE (MDS/MPNI)
per: MM Garcia, et al.
Publicat: (2023-10-01)

Management of neurogenic bladder in myelodysplasia patients: experience at our center
per: Chourishi Vigya, et al.
Publicat: (2010-12-01)

Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas
per: Franziska Lea Schümann, et al.
Publicat: (2021-12-01)

EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy
per: Julian C. Lui, et al.
Publicat: (2016-11-01)

The role of polycomb group protein EZH2 in dendritic cell function.
per: Gunawan, Merry.
Publicat: (2012)

The physiological role of polycomb group protein Ezh2 in dendritic cells
per: Loh, Jia Tong
Publicat: (2016)